ENVB Enveric Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 890821 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.4%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-204.8%
ROA-175.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.78M | $2.84M | $7.25M | $8.03M | $4.79M |
| SG&A expense | $5.79M | $6.45M | $8.85M | $11.61M | $20.50M |
| Operating income | -$8.77M | -$9.63M | -$16.45M | -$27.42M | -$64.62M |
| Interest expense | — | — | — | $5,249 | $10,316 |
| Pretax income | -$8.77M | -$9.57M | -$17.26M | -$19.96M | -$56.43M |
| Income tax | — | $8,930 | $28,913 | -$1.49M | -$7.45M |
| Net income | -$8.77M | -$9.57M | -$17.29M | -$18.47M | -$48.98M |
| EBITDA | -$8.57M | -$9.29M | -$16.10M | -$27.09M | -$63.97M |
| EPS (basic) | -36.24 | -228.48 | -121.29 | -13.00 | -103.69 |
| EPS (diluted) | -36.24 | -228.48 | -121.29 | -13.00 | -2.07 |
| Weighted avg. shares (diluted) | 334,719 | 41,908 | 143,938 | 1.45M | 23.62M |
| Banking | |||||
| Net interest income | -$106 | $219 | $3,708 | -$5,249 | — |
| Balance sheet | |||||
| Cash & equivalents | $4.68M | $2.24M | $2.29M | $17.72M | $17.36M |
| Current assets | $4.94M | $2.73M | $3.58M | $18.43M | $17.74M |
| PP&E, net | $159,234 | $305,777 | $507,377 | $677,485 | $294,430 |
| Goodwill | — | — | — | $379,686 | $1.59M |
| Intangibles | — | $42,182 | $210,932 | $379,686 | $548,436 |
| Total assets | $5.10M | $3.08M | $4.30M | $19.55M | $26.72M |
| Current liabilities | $918,400 | $1.49M | $2.34M | $4.00M | $2.74M |
| Total liabilities | $918,400 | $1.49M | $2.34M | $4.00M | $4.41M |
| Shareholders' equity | $4.18M | $1.59M | $1.96M | $14.67M | $22.31M |
| Shares outstanding | 1.06M | 56,501 | 182,625 | 2.08M | 651,921 |
| Cash flow statement | |||||
| Operating cash flow | -$8.14M | -$7.73M | -$14.09M | -$17.15M | -$11.46M |
| Capital expenditure | — | — | $5,180 | $584,165 | $189,719 |
| Free cash flow | — | — | -$14.10M | -$17.73M | -$11.65M |
| Investing cash flow | — | — | $11,667 | -$584,165 | $2.19M |
| Financing cash flow | $10.58M | $7.67M | -$1.34M | $18.18M | $24.90M |
| Depreciation & amortization | $200,858 | $337,489 | $343,982 | $327,910 | $656,643 |
| Stock-based compensation | $827,323 | $1.56M | $2.15M | $2.62M | $12.60M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.